Sermorelin vs Humanin

Sermorelin and Humanin are both research peptides studied across multiple applications, but they originate from distinct biological pathways and exert their effects through unrelated mechanisms. Sermorelin is a synthetic fragment of growth hormone-releasing hormone (GHRH) that stimulates endogenous growth hormone secretion, with clinical data supporting its use in growth hormone deficiency and body composition studies. Humanin, in contrast, is a mitochondria-derived peptide encoded by mitochondrial DNA, discovered for its neuroprotective properties and implicated in cytoprotective, metabolic, and anti-inflammatory processes. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps, emphasizing that these peptides are not interchangeable but rather complementary tools for distinct research questions.

Sermorelin is a synthetic 29-amino-acid peptide (MW ~3357.9 g/mol) corresponding to the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It was previously FDA-approved as Geref for the diagnosis and treatment of growth hormone deficiency in children, though the product was voluntarily discontinued for commercial reasons — the FDA confirmed in 2013 it was not withdrawn for safety reasons. It preserves the body's natural GH feedback loop via somatostatin, making it safer than exogenous HGH. The 1997 JCEM trial remains the most substantial evidence for its effects in adults, demonstrating improvements in IGF-1, body composition, and well-being over 5 months.

Key claims: Stimulates endogenous growth hormone release; Improves body composition in adults; Improves sleep quality.

Humanin is a 21-24 amino acid mitochondria-derived peptide (MDP) encoded by the MT-RNR2 gene in mitochondrial DNA. It was originally discovered in 2001 for its ability to protect neurons from Alzheimer's disease-related toxicity. Since then, it has been found to have broad cytoprotective, anti-inflammatory, anti-apoptotic, and metabolic effects. Circulating humanin levels decline with age and correlate with longevity in centenarian studies.

Key claims: Neuroprotection against Alzheimer's toxicity; Cardioprotection; Improves insulin sensitivity.

Both peptides are studied for anti-aging applications, but their specific research foci differ substantially. Sermorelin is primarily investigated for body composition, sleep quality, and growth hormone-related aging phenotypes, with clinical evidence supporting its use in adults with growth hormone deficiency. Humanin, on the other hand, is researched for cognitive enhancement, neuroprotection, and metabolic health, with a stronger emphasis on cellular stress resistance and mitochondrial function. Researchers should note that while both target aging, they address distinct aspects: Sermorelin via endocrine modulation and Humanin via mitochondrial and cytoprotective pathways. This distinction is critical for study design and hypothesis generation.

Sermorelin is generally well-tolerated in clinical studies, with safety data from published trials supporting a good tolerability profile. Common adverse effects include injection site reactions (redness, swelling, mild pain) that typically resolve within days. Systemic effects such as headaches, nausea, dizziness, facial flushing, and drowsiness are mild and transient, usually occurring in the initial weeks as the body adjusts. In contrast, Humanin has no formal human safety data, though it is an endogenous peptide naturally present in human circulation. No adverse effects have been reported in animal studies at tested doses, but the absence of clinical trials means its safety profile in humans remains uncharacterized. Researchers should exercise caution and prioritize in vitro or animal models when studying Humanin.